Brought to you by 
Series B raises $17.5mm for VeraLight
10 Jul 2013
Executive Summary
VeraLight (medical devices for diabetes screening) brought in $17.5mm from its Series B financing round led by first-time investor Psilos Group with participation from other new backer CMEA Ventures and returning shareholders vSpring Capital, Wasatch Venture Fund, Dow Chemical, and the Southern Ute Growth Fund. One member each from Psilos and CMEA will each take a seat on the company's board. VeraLight will use the proceeds to finish developing and eventually commercialize its Scout diabetes screening system.
Deal Industry
- In Vitro Diagnostics
- Medical Devices
-
Medical Devices
- Diagnostic Equipment & Supplies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series B raises $17.5mm for VeraLight
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice